Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free BRTXQ Stock Alerts

BioRestorative Therapies (BRTXQ) Financials

BioRestorative Therapies logo
$2.80 -0.16 (-5.31%)
As of 09/8/2026
Compare
Annual Income Statements for BioRestorative Therapies

Annual Income Statements for BioRestorative Therapies

This table shows BioRestorative Therapies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Costs & Expenses		 - - - - - - - - - - 16
Net Income / (Loss) Attributable to Common Shareholders		 - - - -13 -17 -14 -44 -13 -10 -8.98 -14
Consolidated Net Income / (Loss)		 - - - -13 -15 -11 -44 -13 -10 -8.98 -14
Net Income / (Loss) Continuing Operations		 - - - -13 -17 -14 -44 -13 -10 -8.98 -14
Total Pre-Tax Income 		- - - -13 -11 -14 -44 -13 -10 -8.98 -14
Total Operating Income		 - - - -7.65 -8.43 -2.75 -26 -19 -15 -12 -16
Total Gross Profit		 - - - 0.11 0.13 0.08 0.05 0.12 0.15 0.37 0.34
Total Revenue		 - - - 0.11 0.13 0.08 0.05 0.12 0.15 0.40 0.36
Operating Revenue		 - - - 0.11 0.13 0.08 0.05 0.12 0.15 0.40 0.36
Total Cost of Revenue		 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.02
Operating Cost of Revenue		 - - - - - - - - 0.00 0.03 0.02
Total Operating Expenses		 - - - 7.76 8.56 5.66 26 19 15 12 16
Selling, General & Admin Expense		 - - - 5.89 6.52 1.92 26 16 11 5.22 5.89
Research & Development Expense		 - - - 1.51 1.72 0.88 0.73 3.51 4.03 6.71 10
Total Other Income / (Expense), net		 - - - -4.87 -2.43 -8.88 -18 5.75 4.80 2.58 1.41
Interest Expense		 - - - 4.64 3.24 2.30 18 -0.01 -0.55 -0.62 -0.27
Other Income / (Expense), net		 - - - -0.23 0.82 -6.58 0.00 5.74 4.25 1.96 1.14
Basic Earnings per Share		 - - - ($1.64) ($0.66) ($28.56) ($37.30) ($3.65) ($2.47) ($1.16) ($1.58)
Weighted Average Basic Shares Outstanding		 2.47M 4.11M 5.42M 7.63M 22.28M 394.71K 1.19M 3.62M 4.22M 7.76M 8.99M
Diluted Earnings per Share		 - - - ($1.64) ($0.66) ($28.56) - ($3.65) ($2.47) ($1.16) ($1.58)
Weighted Average Diluted Shares Outstanding		 2.47M 4.11M 5.42M 7.63M 22.28M 394.71K 1.19M 3.62M 4.22M 7.76M 8.99M
Weighted Average Basic & Diluted Shares Outstanding		 2.47M 4.11M 5.42M 7.63M 22.28M 394.71K 1.19M 3.77M 6.77M 7.50M 25.48M

Quarterly Income Statements for BioRestorative Therapies

This table shows BioRestorative Therapies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Total Costs & Expenses		 - - - - - - - - - - 3.40
Net Income / (Loss) Attributable to Common Shareholders		 4.77 -2.30 -2.22 -4.03 -1.09 -1.64 -5.34 -2.66 -3.04 -3.21 -2.15
Consolidated Net Income / (Loss)		 4.77 -2.30 -2.22 -4.03 -1.09 -1.64 -5.34 -2.66 -3.04 -3.21 -2.15
Net Income / (Loss) Continuing Operations		 4.77 -2.30 -2.22 -4.03 -1.09 -1.64 -5.34 -2.66 -3.04 -3.21 -2.15
Total Pre-Tax Income 		4.77 -2.30 -2.22 -4.03 -1.09 -1.64 -5.34 -2.66 -3.04 -3.21 -2.15
Total Operating Income		 -3.10 -3.22 -4.11 -2.47 -2.29 -2.69 -4.81 -3.31 -3.71 -3.83 -3.39
Total Gross Profit		 0.03 0.02 0.04 0.08 0.22 0.04 0.02 0.29 0.00 0.02 0.02
Total Revenue		 0.03 0.02 0.04 0.09 0.23 0.04 0.03 0.30 0.01 0.02 0.02
Operating Revenue		 0.03 0.02 0.04 0.09 0.23 0.04 0.03 0.30 0.01 0.02 0.02
Total Cost of Revenue		 0.00 - 0.00 0.01 0.02 0.00 0.00 0.01 0.01 0.00 0.01
Operating Cost of Revenue		 0.00 - 0.00 0.01 0.02 0.00 0.00 0.01 0.01 0.00 0.01
Total Operating Expenses		 3.14 3.24 4.14 2.55 2.50 2.73 4.83 3.60 3.71 3.84 3.40
Selling, General & Admin Expense		 2.33 2.15 3.09 1.10 1.05 -0.01 2.18 1.37 1.12 0.28 1.48
Research & Development Expense		 0.81 1.09 1.06 1.45 1.45 2.74 2.65 2.23 2.59 3.56 1.93
Total Other Income / (Expense), net		 7.87 0.92 1.89 -1.56 1.20 1.05 -0.53 0.65 0.67 0.62 1.23
Other Income / (Expense), net		 7.81 0.54 1.72 -1.74 1.04 0.94 -0.63 0.58 0.61 0.58 1.23
Basic Earnings per Share		 $1.04 ($0.11) ($0.33) ($0.50) ($0.13) ($0.20) ($0.64) ($0.30) ($0.33) ($0.31) ($0.12)
Weighted Average Basic Shares Outstanding		 4.57M 4.22M 6.67M 8.12M 8.12M 7.76M 8.36M 8.74M 9.12M 8.99M 17.73M
Diluted Earnings per Share		 $0.39 $0.54 ($0.33) ($0.50) ($0.13) ($0.20) ($0.64) ($0.30) ($0.33) ($0.31) ($0.12)
Weighted Average Diluted Shares Outstanding		 12.32M 4.22M 6.67M 8.12M 8.12M 7.76M 8.36M 8.74M 9.12M 8.99M 17.73M
Weighted Average Basic & Diluted Shares Outstanding		 4.71M 6.77M 6.77M 6.92M 6.92M 7.50M 7.50M 7.98M 8.88M 25.48M 25.48M

Annual Cash Flow Statements for BioRestorative Therapies

This table details how cash moves in and out of BioRestorative Therapies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 - - - -0.33 -3.91 3.06 18 -19 -0.83 -0.34 0.96
Net Cash From Operating Activities		 - - - -5.10 -6.92 -1.96 -3.33 -5.91 -6.43 -8.23 -11
Net Cash From Continuing Operating Activities		 - - - -5.10 -11 -1.96 -3.33 -5.91 -6.43 -8.23 -11
Net Income / (Loss) Continuing Operations		 - - - -13 -15 -11 -44 -13 -10 -8.98 -14
Consolidated Net Income / (Loss)		 - - - -13 -15 -11 -44 -13 -10 -8.98 -14
Depreciation Expense		 - - - 0.24 0.22 0.12 0.09 0.12 0.17 0.19 0.21
Non-Cash Adjustments To Reconcile Net Income		 - - - 4.93 3.32 7.34 39 7.17 3.31 0.53 1.93
Changes in Operating Assets and Liabilities, net		 - - - -0.05 0.52 0.57 0.32 0.01 0.52 0.03 1.31
Net Cash From Investing Activities		 - - - -0.01 -0.04 0.00 -0.03 -13 3.25 0.51 8.90
Net Cash From Continuing Investing Activities		 - - - -0.01 -0.04 0.00 -0.03 -13 3.25 0.51 8.90
Purchase of Property, Plant & Equipment		 - - - -0.01 -0.04 0.00 -0.03 -0.27 -0.17 -0.11 -0.12
Purchase of Investments		 - - - - - - 0.00 -22 -18 -21 -2.68
Sale and/or Maturity of Investments		 - - - - - - - 9.49 21 22 12
Net Cash From Financing Activities		 - - - 4.78 6.84 5.03 21 0.00 2.35 7.38 2.85
Net Cash From Continuing Financing Activities		 - - - 4.78 6.84 5.03 21 0.00 2.35 7.38 2.85
Repurchase of Common Equity		 - - - - - - - - - 0.00 -0.18
Issuance of Debt		 - - - 5.10 11 4.29 0.00 - 0.00 7.53 0.00
Issuance of Common Equity		 - - - 0.18 1.66 0.01 21 0.00 2.35 0.00 3.10
Other Financing Activities, net		 - - - 0.41 - 1.23 - - 0.00 -0.15 -0.06
Cash Interest Paid		 - - - 0.04 0.36 0.00 - 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 - - - - - 0.00 - 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for BioRestorative Therapies

This table details how cash moves in and out of BioRestorative Therapies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.65 -1.59 0.27 1.10 -0.76 -0.94 0.68 0.33 -0.95 0.91 1.60
Net Cash From Operating Activities		 -1.18 -1.59 -2.32 -1.87 -1.70 -2.35 -2.78 -2.69 -2.90 -2.42 -3.81
Net Cash From Continuing Operating Activities		 -1.18 -1.59 -2.32 -1.87 -1.70 -2.35 -2.78 -2.69 -2.90 -2.42 -3.81
Net Income / (Loss) Continuing Operations		 4.77 -2.30 -2.22 -4.03 -1.09 -1.64 -5.34 -2.66 -3.04 -3.21 -2.15
Consolidated Net Income / (Loss)		 4.77 -2.30 -2.22 -4.03 -1.09 -1.64 -5.34 -2.66 -3.04 -3.21 -2.15
Depreciation Expense		 0.04 0.04 0.04 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Non-Cash Adjustments To Reconcile Net Income		 -6.17 0.54 0.34 1.92 -0.88 -0.85 2.54 -0.18 -0.27 -0.16 -0.94
Changes in Operating Assets and Liabilities, net		 0.18 0.13 -0.48 0.19 0.22 0.09 -0.03 0.09 0.36 0.90 -0.77
Net Cash From Investing Activities		 -0.02 -0.08 -4.93 2.97 0.94 1.53 2.37 2.13 2.00 2.40 0.97
Net Cash From Continuing Investing Activities		 -0.02 -0.08 -4.93 2.97 0.94 1.53 2.37 2.13 2.00 2.40 0.97
Purchase of Property, Plant & Equipment		 -0.01 -0.07 0.00 -0.04 -0.06 -0.01 -0.04 - - -0.08 0.00
Purchase of Investments		 -7.12 -2.89 -11 -2.06 -5.51 -2.59 -1.05 -1.08 -0.55 - -0.07
Sale and/or Maturity of Investments		 7.11 2.88 5.80 5.07 6.51 4.14 3.46 3.21 2.55 2.48 1.04
Net Cash From Financing Activities		 1.85 0.08 7.52 -0.01 - -0.13 1.09 0.89 -0.05 0.92 4.44
Net Cash From Continuing Financing Activities		 1.85 0.08 7.52 -0.01 - -0.13 1.09 0.89 -0.05 0.92 4.44
Repurchase of Common Equity		 - - 0.00 - - - -0.03 -0.04 - -0.11 -0.56
Issuance of Common Equity		 1.85 0.08 0.00 - - - 1.08 0.93 - 1.09 5.00
Other Financing Activities, net		 - - -0.01 -0.01 - -0.13 0.04 - -0.05 -0.06 0.00
Cash Interest Paid		 - - 0.00 - - - 0.00 - - - 0.00
Cash Income Taxes Paid		 - - 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for BioRestorative Therapies

This table presents BioRestorative Therapies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 - - - 1.19 1.47 4.35 22 16 13 12 4.08
Total Current Assets		 - - - 0.18 0.07 3.19 21 15 11 11 3.14
Cash & Equivalents		 - - - 0.12 0.00 3.06 21 1.71 0.88 0.55 1.51
Short-Term Investments		 - - - - - - 0.00 13 10 10 1.44
Accounts Receivable		 - - - 0.03 0.03 0.02 0.01 0.02 0.02 0.19 0.02
Prepaid Expenses		 - - - 0.03 0.04 0.11 0.44 0.36 0.31 0.22 0.17
Plant, Property, & Equipment, net		 - - - 0.00 0.00 0.02 0.04 0.26 0.36 0.36 0.36
Total Noncurrent Assets		 - - - 0.81 1.40 1.14 0.95 1.05 0.87 0.77 0.58
Intangible Assets		 - - - 0.81 0.74 0.66 0.59 0.80 0.71 0.62 0.53
Other Noncurrent Operating Assets		 - - - 0.00 0.66 0.47 0.36 0.24 0.15 0.15 0.05
Total Liabilities & Shareholders' Equity		 - - - 1.19 1.47 4.35 22 16 13 12 4.08
Total Liabilities		 - - - 9.83 14 5.68 0.86 6.14 2.61 3.75 3.72
Total Current Liabilities		 - - - 9.25 14 1.04 0.36 5.98 2.61 3.75 3.72
Accounts Payable		 - - - 1.89 1.95 0.12 0.05 0.17 0.19 0.48 1.34
Accrued Expenses		 - - - 2.30 2.92 0.77 0.13 0.13 0.71 0.74 0.98
Other Current Liabilities		 - - - 1.09 1.00 0.16 0.12 5.68 1.71 2.52 1.40
Total Noncurrent Liabilities		 - - - 0.52 0.52 4.63 0.49 0.16 0.00 0.00 0.00
Commitments & Contingencies		 - - - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 - - - -8.64 -13 -1.33 22 10 10 8.53 0.36
Total Preferred & Common Equity		 - - - -8.64 -13 -1.33 22 10 10 8.53 0.36
Preferred Stock		 - - - 0.00 0.00 0.00 0.02 0.02 0.01 0.01 0.01
Total Common Equity		 - - - -8.64 -13 -1.33 22 10 9.99 8.52 0.34
Common Stock		 - - - 55 66 89 156 147 157 164 170
Retained Earnings		 - - - -64 -79 -90 -134 -136 -147 -156 -170

Quarterly Balance Sheets for BioRestorative Therapies

This table presents BioRestorative Therapies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 14 18 16 15 10 8.52 5.64 4.64
Total Current Assets		 13 17 15 14 9.36 7.60 4.71 3.80
Cash & Equivalents		 2.44 1.16 2.25 1.49 1.23 1.56 0.60 3.11
Short-Term Investments		 9.80 15 12 12 7.88 5.83 3.89 0.48
Accounts Receivable		 0.04 0.04 0.03 0.17 0.03 0.02 0.01 0.01
Prepaid Expenses		 0.33 0.32 0.30 0.23 0.22 0.20 0.20 0.19
Plant, Property, & Equipment, net		 0.31 0.37 0.35 0.38 0.37 0.34 0.31 0.33
Total Noncurrent Assets		 0.89 0.82 0.77 0.69 0.60 0.58 0.63 0.51
Intangible Assets		 0.74 0.69 0.67 0.65 0.60 0.58 0.56 0.51
Other Noncurrent Operating Assets		 0.15 0.12 0.10 0.04 0.00 0.00 0.07 0.00
Total Liabilities & Shareholders' Equity		 14 18 16 15 10 8.52 5.64 4.64
Total Liabilities		 0.98 3.45 5.32 4.58 4.18 3.67 3.44 1.61
Total Current Liabilities		 0.93 3.45 5.32 4.58 4.18 3.67 3.44 1.61
Accounts Payable		 0.23 0.23 0.22 0.40 0.60 0.61 0.86 0.67
Accrued Expenses		 0.55 0.34 0.45 0.68 0.28 0.48 0.61 0.95
Other Current Liabilities		 0.16 2.88 4.58 3.50 3.15 2.58 1.97 0.00
Total Noncurrent Liabilities		 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 13 15 11 9.99 6.14 4.85 2.21 3.03
Total Preferred & Common Equity		 13 15 11 9.99 6.14 4.85 2.21 3.03
Preferred Stock		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00
Total Common Equity		 13 14 11 9.98 6.13 4.83 2.19 3.03
Common Stock		 177 163 164 164 167 169 169 175
Retained Earnings		 -164 -149 -153 -154 -161 -164 -167 -172

Annual Metrics And Ratios for BioRestorative Therapies

This table displays calculated financial ratios and metrics derived from BioRestorative Therapies' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 3,133,329.00 4,557,430.00 5,658,856.00 10,453,936.00 30,761,527.00 30,761,527.00 3,492,985.00 3,673,629.00 4,706,917.00 6,919,919.00 8,876,242.00
DEI Adjusted Shares Outstanding		 3,133,329.00 4,557,430.00 5,658,856.00 10,453,936.00 30,761,527.00 30,761,527.00 3,492,985.00 3,673,629.00 4,706,917.00 6,919,919.00 8,876,242.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - -1.20 -0.56 -0.47 -12.68 -3.60 -2.21 -1.30 -1.60
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 17.12% -40.77% -40.26% 160.43% 21.70% 175.03% -10.30%
EBITDA Growth		 0.00% 0.00% 0.00% 0.00% 30.37% -112.95% -216.21% 47.72% 17.61% 12.94% -52.01%
EBIT Growth		 0.00% 0.00% 0.00% 0.00% 3.38% -22.57% -181.89% 49.70% 17.11% 12.53% -51.20%
NOPAT Growth		 0.00% 0.00% 0.00% 0.00% -10.26% 67.36% -855.93% 27.88% 19.78% 24.08% -35.41%
Net Income Growth		 0.00% 0.00% 0.00% 0.00% -17.02% 23.04% -293.01% 70.16% 21.21% 13.81% -58.61%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 59.76% -4,227.27% 0.00% 0.00% 32.33% 53.04% -36.21%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% -35.54% 71.61% -69.52% -77.58% -8.75% -28.00% -31.09%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% -472.31% -25.15% -187.48% 58.67% -75.59% 50.55% -51.93%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% -11.81% 97.45% 751.65% -643.64% 76.19% -107.34% -17.94%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -16.30% -20.69% -1.07% 11.98% 6.37% -6.18%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -586.73% -15.14% 27.91% -47.48% 9.02% -11.59%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -24,644.17% -13.59% 27.69% -46.64% 8.79% -11.42%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 52.39% -13.59% -3.68% 8.76% 4.39% -7.82%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -59.63% -49.36% 61.73% -44.92% 6.92% -12.40%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -1,313.86% 0.00% 0.00% 0.00% -176.19% -7.48%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 38.68% -20.78% -8.65% 0.43% -10.17% -0.63%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -160.15% 39.25% 38.03% -19.62% -45.48% 3.77%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 99.17% 97.50% -961.59% -280.74% 28.90% -13.73%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 93.00% 93.37%
EBITDA Margin		 0.00% 0.00% 0.00% -4,819.92% -2,865.61% -10,302.63% -54,533.10% -10,946.08% -7,410.33% -2,345.74% -3,975.03%
Operating Margin		 0.00% 0.00% 0.00% -6,889.78% -6,486.16% -3,574.12% -57,191.03% -15,838.08% -10,439.49% -2,881.59% -4,350.05%
EBIT Margin		 0.00% 0.00% 0.00% -7,099.17% -5,856.72% -12,120.14% -57,191.03% -11,046.70% -7,524.00% -2,392.88% -4,033.41%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -11,277.30% -11,267.61% -14,639.85% -96,311.51% -11,036.98% -7,145.20% -2,239.25% -3,959.40%
Tax Burden Percent		 0.00% 0.00% 0.00% 100.00% 134.91% 77.96% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 0.00% 0.00% 0.00% 158.85% 142.61% 154.94% 168.40% 99.91% 94.97% 93.58% 98.17%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,304.37% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,039.81% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,867.14% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 289.73% 136.79% 159.81% -437.23% -82.93% -102.66% -96.89% -320.47%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,360.53% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -1,321.74% -572.74% -321.07% -196.32% -68.06% -75.53% -77.10% -177.37%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -2,099.63% -1,101.88% -387.82% -330.62% -68.00% -71.73% -72.15% -174.11%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 289.73% 136.79% 159.81% -436.90% -82.85% -102.52% -96.74% -319.46%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 144.86% 114.65% 846.62% -205.14% -128.49% -104.13% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.00 0.00 0.00 -5.35 -5.90 -1.93 -18 -13 -11 -8.09 -11
NOPAT Margin		 0.00% 0.00% 0.00% -4,822.84% -4,540.31% -2,501.89% -40,033.72% -11,086.66% -7,307.64% -2,017.12% -3,045.04%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% 338.91% 144.91% 206.60% -264.55% 0.34% 1.83% -8.17% -48.07%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -106.50% -94.81% -3,070.27%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.00% 6.63%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 5,309.28% 5,014.14% 2,498.66% 55,706.12% 13,005.40% 7,772.28% 1,302.05% 1,637.01%
R&D to Revenue		 0.00% 0.00% 0.00% 1,363.20% 1,324.88% 1,138.74% 1,584.91% 2,932.68% 2,767.21% 1,672.55% 2,806.41%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 6,989.78% 6,586.16% 7,348.25% 57,291.03% 15,938.08% 10,539.49% 2,974.59% 4,443.42%
Earnings before Interest and Taxes (EBIT)		 0.00 0.00 0.00 -7.88 -7.61 -9.33 -26 -13 -11 -9.60 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.00 0.00 0.00 -5.35 -3.73 -7.93 -25 -13 -11 -9.41 -14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.70 0.98 0.82 1.16 30.43
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.72 1.07 0.88 1.25 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 97.95 1.18 0.08 329.56 84.33 56.17 24.68 29.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 134.27 56.14 15.74 0.00 0.00 0.00 0.00 20.82
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 -0.48 -0.56 -3.21 0.01 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 -0.06 0.00 -3.21 0.01 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.00 -0.49 -0.56 -0.64 -0.97 -1.11 -1.27 -1.18 -1.54
Leverage Ratio		 0.00 0.00 0.00 -0.14 -0.12 -0.41 1.32 1.22 1.43 1.34 1.84
Compound Leverage Factor		 0.00 0.00 0.00 -0.22 -0.18 -0.64 2.23 1.22 1.36 1.26 1.81
Debt to Total Capital		 0.00% 0.00% 0.00% -92.39% -126.92% 145.31% 1.14% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% -80.72% -126.92% 0.00% 0.27% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% -11.66% 0.00% 145.31% 0.87% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.07% 0.15% 0.14% 0.16% 3.92%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 192.39% 226.92% -45.31% 98.79% 99.85% 99.86% 99.84% 96.08%
Debt to EBITDA		 0.00 0.00 0.00 -0.78 -1.92 -0.54 -0.01 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 -0.75 -1.92 -0.15 0.83 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.10 0.00 -0.54 -0.01 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.78 -1.21 -2.22 -0.01 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 -0.75 -1.21 -0.63 1.13 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.10 0.00 -2.22 -0.01 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -105.24 -103.23 -35.41 -0.48 -12.60 -16.42 -17.99 -68.45
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.08% 0.10% 0.14% 0.15% 0.31%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 0.02 0.01 3.05 59.01 2.53 4.37 2.97 0.84
Quick Ratio		 0.00 0.00 0.00 0.02 0.00 2.95 57.81 2.47 4.25 2.91 0.80
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 -0.94 -5.38 -6.73 -19 -8.00 -14 -6.95 -11
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% -39,666.09% -19,417.74% 0.00% -10,861.47% -2,229.48% -3,759.41% -7,750.66% -9,295.30%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -0.20 -1.66 -2.93 -1.08 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -1.10 -2.13 -0.85 -0.19 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -1.10 -2.14 -0.85 -0.19 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.19 0.10 0.03 0.00 0.01 0.01 0.03 0.04
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 4.26 3.14 4.18 11.41 8.26 3.86 3.53
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 1.54 0.80 0.47 1.12 1.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.03
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 85.63 116.14 87.28 31.99 44.19 94.53 103.45
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4,371.75 13,965.07
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 85.63 116.14 87.28 31.99 44.19 -4,277.22 -13,861.62
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -4.41 -4.93 -0.13 0.82 -4.46 -1.06 -2.20 -2.60
Invested Capital Turnover		 0.00 0.00 0.00 -0.05 -0.03 -0.03 0.13 -0.07 -0.05 -0.25 -0.15
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 -4.41 -0.52 4.81 0.95 -5.28 3.40 -1.14 -0.39
Enterprise Value (EV)		 1.05 1.53 1.90 15 7.30 1.21 -5.60 -4.63 -2.86 -0.82 7.49
Market Capitalization		 1.05 1.53 1.90 11 0.15 0.01 15 10 8.19 9.90 10
Book Value per Share		 $0.00 $0.00 $0.00 ($0.83) ($0.42) ($0.04) $6.18 $2.80 $2.12 $1.23 $0.04
Tangible Book Value per Share		 $0.00 $0.00 $0.00 ($0.90) ($0.44) ($0.06) $6.01 $2.58 $1.97 $1.14 ($0.02)
Total Capital		 0.00 0.00 0.00 -4.49 -5.63 2.94 22 10 10 8.53 0.36
Total Debt		 0.00 0.00 0.00 4.15 7.15 4.27 0.25 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.52 0.00 4.27 0.19 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.00 4.03 7.14 1.21 -21 -15 -11 -11 -2.95
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.01 0.04 0.00 0.03 0.27 0.17 0.11 0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -5.57 -6.51 -0.92 0.14 -5.60 -2.28 -3.34 -3.54
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 -5.45 -6.51 2.14 21 9.15 8.78 7.40 -0.59
Net Working Capital (NWC)		 0.00 0.00 0.00 -9.07 -14 2.14 21 9.15 8.78 7.40 -0.59
Net Nonoperating Expense (NNE)		 0.00 0.00 0.00 7.16 8.75 9.35 26 -0.06 -0.24 0.89 3.29
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 4.23 7.84 1.21 -21 -15 -11 -11 -2.95
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 2.53 3.89 1.40 1.22 0.12 0.17 0.19 0.21
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -5,014.20% -5,005.75% -1,197.90% 296.37% -4,676.92% -1,565.72% -832.11% -983.86%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -4,908.33% -5,004.47% 2,782.12% 46,006.64% 7,634.77% 6,024.13% 1,844.34% -162.92%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% -8,174.69% -10,501.32% 2,782.12% 45,878.45% 7,634.77% 6,024.13% 1,844.34% -162.92%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.20) ($2.10) ($1.74) ($1.64) ($0.66) ($0.01) ($37.30) ($5.11) $0.00 ($1.16) ($1.58)
Adjusted Weighted Average Basic Shares Outstanding		 3.93M 5.28M 6.48M 14.68M 22.28M 394.71K 3.63M 3.62M 0.00 7.76M 8.99M
Adjusted Diluted Earnings per Share		 ($3.20) ($2.10) ($1.74) ($1.64) ($0.66) ($0.01) ($37.30) $0.00 $0.00 ($1.16) ($1.58)
Adjusted Weighted Average Diluted Shares Outstanding		 3.93M 5.28M 6.48M 14.68M 22.28M 394.71K 3.63M 3.77M 0.00 7.76M 8.99M
Adjusted Basic & Diluted Earnings per Share		 ($3.20) ($2.10) ($1.74) ($1.64) ($0.66) ($0.01) ($37.30) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.47M 4.11M 5.42M 7.63M 22.28M 1.58B 1.19M 3.77M 0.00 7.50M 25.48M
Normalized Net Operating Profit after Tax (NOPAT)		 0.00 0.00 0.00 -5.35 -5.90 -1.93 -18 -13 -11 -8.09 -11
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -4,822.84% -4,540.31% -2,501.89% -40,033.72% -11,086.66% -7,307.64% -2,017.12% -3,045.04%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -11,277.30% -8,352.04% -18,779.07% -96,311.51% -11,036.98% -7,145.20% -2,239.25% -3,959.40%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -1.70 -2.35 -4.06 -1.46 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -1.15 -1.82 -0.84 -1.02 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -1.70 -2.36 -4.06 -1.46 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -1.16 -1.83 -0.84 -1.03 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.25%

Quarterly Metrics And Ratios for BioRestorative Therapies

This table displays calculated financial ratios and metrics derived from BioRestorative Therapies' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 4,667,641.00 4,706,917.00 13,539,838.00 6,769,919.00 6,919,919.00 6,919,919.00 7,504,780.00 7,504,780.00 7,978,117.00 8,876,242.00 25,478,170.00
DEI Adjusted Shares Outstanding		 4,667,641.00 4,706,917.00 13,539,838.00 6,769,919.00 6,919,919.00 6,919,919.00 7,504,780.00 7,504,780.00 7,978,117.00 8,876,242.00 25,478,170.00
DEI Earnings Per Adjusted Shares Outstanding		 1.02 -0.49 -0.16 -0.60 -0.16 -0.24 -0.71 -0.35 -0.38 -0.36 -0.08
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 5.86% 421.62% 11.82% 38.14% 660.91% 124.35% -28.57% 240.40% -94.95% -54.73% -7.32%
EBITDA Growth		 203.33% -413.76% 67.24% 27.88% -125.31% 35.36% -129.97% 35.59% -153.26% -87.09% 60.89%
EBIT Growth		 201.72% -431.38% 66.82% 27.58% -126.56% 34.52% -128.03% 35.07% -147.69% -84.73% 60.30%
NOPAT Growth		 3.79% 51.85% 28.89% 20.78% 48.43% 16.47% -16.99% -33.88% -62.18% -42.20% 29.57%
Net Income Growth		 202.42% -349.10% 69.00% 29.44% -122.89% 28.99% -140.18% 34.06% -178.38% -96.05% 59.65%
EPS Growth		 130.47% 0.00% 82.90% 65.99% -133.33% -137.04% -93.94% 40.00% -153.85% -55.00% 81.25%
Operating Cash Flow Growth		 18.75% 1.72% 2.58% -45.31% -44.10% -47.85% -19.89% -44.43% -70.70% -2.87% -37.03%
Free Cash Flow Firm Growth		 4.65% -1,046.11% 103.50% 226.90% 165.60% 86.84% -1,626.27% -224.40% -263.72% -207.02% -106.39%
Invested Capital Growth		 13.49% 76.19% -272.06% -592.25% -627.09% -107.34% -55.00% 34.67% 26.26% -17.94% 80.92%
Revenue Q/Q Growth		 -52.40% -37.13% 81.35% 154.57% 162.18% -81.46% -42.26% 1,113.20% -96.11% 66.10% 18.21%
EBITDA Q/Q Growth		 182.39% -155.54% 11.16% -77.40% 71.09% -41.86% -216.09% 50.31% -13.67% -4.80% 33.92%
EBIT Q/Q Growth		 181.07% -156.95% 10.98% -76.23% 70.27% -40.42% -209.97% 49.81% -13.40% -4.72% 33.38%
NOPAT Q/Q Growth		 -42.30% 27.38% -27.59% 39.92% 7.36% -17.63% -78.71% 31.25% -12.21% -3.14% 11.49%
Net Income Q/Q Growth		 183.52% -148.32% 3.50% -81.20% 72.91% -49.91% -226.36% 50.26% -14.38% -5.57% 32.84%
EPS Q/Q Growth		 126.53% 38.46% -161.11% -51.52% 74.00% -53.85% -220.00% 53.13% -10.00% 6.06% 61.29%
Operating Cash Flow Q/Q Growth		 8.11% -34.64% -45.96% 19.53% 8.88% -38.14% -18.35% 3.06% -7.69% 16.75% -57.66%
Free Cash Flow Firm Q/Q Growth		 -36.93% -78.05% 102.68% 1,841.92% -29.21% -135.70% -210.96% -58.28% 6.83% 33.05% -109.04%
Invested Capital Q/Q Growth		 -25.51% -280.74% -80.38% -102.69% 20.24% 28.90% -34.84% 14.57% 9.97% -13.73% 78.18%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 92.72% 92.19% 92.29% 88.36% 97.12% 10.42% 91.65% 68.13%
EBITDA Margin		 15,468.21% -13,665.82% -6,694.68% -4,665.32% -514.42% -3,937.11% -21,554.50% -882.77% -25,791.50% -16,272.38% -9,095.77%
Operating Margin		 -10,112.19% -16,687.47% -11,740.72% -2,770.83% -979.02% -6,212.80% -19,230.14% -1,089.77% -31,432.30% -19,516.84% -14,612.57%
EBIT Margin		 15,330.93% -13,887.13% -6,816.72% -4,718.86% -535.09% -4,053.43% -21,761.63% -900.16% -26,237.43% -16,541.95% -9,321.90%
Profit (Net Income) Margin		 15,531.79% -11,937.79% -6,352.16% -4,521.39% -467.22% -3,778.63% -21,359.20% -875.79% -25,748.11% -16,365.49% -9,298.25%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.31% 85.96% 93.19% 95.82% 87.32% 93.22% 98.15% 97.29% 98.14% 98.93% 99.75%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -2,383.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -2,438.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 2,347.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -35.49% -102.66% -39.07% -32.65% -84.56% -96.89% -117.16% -137.09% -207.73% -320.47% -241.14%
Cash Return on Invested Capital (CROIC)		 -2,126.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 125.85% -139.41% -63.63% -55.85% -14.22% -130.60% -601.79% -44.23% -995.19% -727.43% -445.78%
Return on Assets (ROA)		 127.50% -119.84% -59.29% -53.51% -12.42% -121.75% -590.66% -43.03% -976.63% -719.67% -444.65%
Return on Common Equity (ROCE)		 -35.45% -102.52% -39.03% -32.61% -84.45% -96.74% -117.00% -136.85% -207.26% -319.46% -240.77%
Return on Equity Simple (ROE_SIMPLE)		 -56.05% 0.00% -37.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.10 -2.25 -2.88 -1.73 -1.60 -1.88 -3.37 -2.31 -2.60 -2.68 -2.37
NOPAT Margin		 -10,112.19% -11,681.23% -8,218.50% -1,939.58% -685.31% -4,348.96% -13,461.10% -762.84% -22,002.61% -13,661.79% -10,228.80%
Net Nonoperating Expense Percent (NNEP)		 54.81% -0.38% 4.54% -17.50% 4.02% 2.27% -15.47% -3.11% -5.03% -7.74% 3.39%
Return On Investment Capital (ROIC_SIMPLE)		 - -22.53% -19.83% -16.00% -16.02% -22.07% -54.77% -47.75% -117.64% -750.60% -78.33%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 7.28% 7.81% 7.71% 11.64% 2.88% 89.58% 8.35% 31.87%
SG&A Expenses to Revenue		 7,574.33% 11,139.12% 8,817.49% 1,231.67% 449.05% -26.13% 8,730.90% 453.01% 9,453.31% 1,446.69% 6,366.88%
R&D to Revenue		 2,637.86% 5,648.35% 3,023.23% 1,631.87% 622.16% 6,331.22% 10,587.60% 733.89% 21,989.41% 18,161.80% 8,313.82%
Operating Expenses to Revenue		 10,212.19% 16,787.47% 11,840.72% 2,863.54% 1,071.21% 6,305.09% 19,318.50% 1,186.90% 31,442.72% 19,608.49% 14,680.70%
Earnings before Interest and Taxes (EBIT)		 4.71 -2.68 -2.39 -4.20 -1.25 -1.76 -5.44 -2.73 -3.10 -3.24 -2.16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 4.75 -2.64 -2.34 -4.16 -1.20 -1.70 -5.39 -2.68 -3.04 -3.19 -2.11
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.65 0.82 0.64 1.27 1.21 1.16 2.18 2.59 5.28 30.43 2.29
Price to Tangible Book Value (P/TBV)		 0.69 0.88 0.68 1.36 1.29 1.25 2.42 2.94 7.07 0.00 2.76
Price to Revenue (P/Rev)		 64.17 56.17 62.49 78.94 31.94 24.68 34.17 20.65 30.17 29.00 19.37
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 10.89 8.48 18.50 20.82 9.33
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.96 -1.27 -1.03 -1.13 -1.11 -1.18 -1.24 -1.41 -1.44 -1.54 -1.39
Leverage Ratio		 1.06 1.43 1.14 1.27 1.24 1.34 1.37 1.57 1.66 1.84 1.63
Compound Leverage Factor		 1.08 1.23 1.07 1.21 1.09 1.25 1.34 1.53 1.63 1.82 1.63
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.11% 0.14% 0.10% 0.13% 0.14% 0.16% 0.23% 0.29% 0.63% 3.92% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.89% 99.86% 99.90% 99.87% 99.86% 99.84% 99.77% 99.71% 99.37% 96.08% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -9.37 -14.25 -9.53 -11.86 -12.74 -15.88 -21.01 -25.30 -40.82 -59.34 -50.23
Noncontrolling Interest Sharing Ratio		 0.10% 0.14% 0.10% 0.12% 0.12% 0.15% 0.14% 0.18% 0.23% 0.31% 0.15%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.51 4.37 4.86 2.82 2.95 2.97 2.24 2.07 1.37 0.84 2.35
Quick Ratio		 13.17 4.25 4.77 2.76 2.89 2.91 2.19 2.01 1.31 0.80 2.23
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.17 -5.65 0.15 2.94 2.08 -0.74 -2.31 -3.66 -3.41 -2.28 -4.77
Operating Cash Flow to CapEx		 -9,871.26% -2,267.74% 0.00% -5,284.35% -2,907.26% -18,882.46% -7,634.03% 0.00% 0.00% -3,031.51% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.01 0.01 0.03 0.03 0.03 0.05 0.04 0.04 0.05
Accounts Receivable Turnover		 3.09 8.26 5.86 6.65 3.69 3.86 13.03 28.55 4.30 3.53 18.69
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.48 0.47 0.45 0.53 1.10 1.12 1.06 1.77 1.11 1.00 1.02
Accounts Payable Turnover		 0.00 0.00 0.00 0.03 0.08 0.08 0.07 0.08 0.04 0.03 0.04
Days Sales Outstanding (DSO)		 118.16 44.19 62.26 54.93 98.90 94.53 28.01 12.79 84.92 103.45 19.53
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 13,834.23 4,639.31 4,371.75 4,891.66 4,536.96 9,010.18 13,965.07 8,160.93
Cash Conversion Cycle (CCC)		 118.16 44.19 62.26 -13,779.30 -4,540.41 -4,277.22 -4,863.65 -4,524.17 -8,925.26 -13,861.62 -8,141.40
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.59 -1.06 -1.91 -3.88 -3.10 -2.20 -2.97 -2.54 -2.28 -2.60 -0.57
Invested Capital Turnover		 0.24 -0.05 -0.37 -0.11 -0.30 -0.25 -0.16 -0.19 -0.14 -0.15 -0.20
Increase / (Decrease) in Invested Capital		 0.07 3.40 -3.03 -4.67 -3.68 -1.14 -1.05 1.35 0.81 -0.39 2.40
Enterprise Value (EV)		 -3.87 -2.86 -7.06 -0.92 -1.03 -0.82 4.26 5.13 7.09 7.49 3.34
Market Capitalization		 8.36 8.19 9.34 14 12 9.90 13 12 12 10 6.93
Book Value per Share		 $2.74 $2.12 $2.14 $1.59 $1.44 $1.23 $0.82 $0.64 $0.27 $0.04 $0.12
Tangible Book Value per Share		 $2.59 $1.97 $2.04 $1.49 $1.35 $1.14 $0.74 $0.57 $0.21 ($0.02) $0.10
Total Capital		 13 10 15 11 9.99 8.53 6.14 4.85 2.21 0.36 3.03
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -12 -11 -16 -15 -13 -11 -9.11 -7.38 -4.49 -2.95 -3.59
Capital Expenditures (CapEx)		 0.01 0.07 0.00 0.04 0.06 0.01 0.04 0.00 0.00 0.08 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.57 -2.28 -3.10 -5.00 -4.16 -3.34 -3.94 -3.45 -3.22 -3.54 -1.41
Debt-free Net Working Capital (DFNWC)		 12 8.78 13 9.68 8.93 7.40 5.17 3.93 1.27 -0.59 2.19
Net Working Capital (NWC)		 12 8.78 13 9.68 8.93 7.40 5.17 3.93 1.27 -0.59 2.19
Net Nonoperating Expense (NNE)		 -7.87 0.05 -0.65 2.30 -0.51 -0.25 1.97 0.34 0.44 0.53 -0.22
Net Nonoperating Obligations (NNO)		 -12 -11 -16 -15 -13 -11 -9.11 -7.38 -4.49 -2.95 -3.59
Total Depreciation and Amortization (D&A)		 0.04 0.04 0.04 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Debt-free, Cash-free Net Working Capital to Revenue		 -435.78% -1,565.72% -2,071.02% -2,869.92% -1,103.57% -832.11% -1,007.59% -570.78% -839.34% -983.86% -393.15%
Debt-free Net Working Capital to Revenue		 8,964.15% 6,024.13% 8,911.12% 5,562.28% 2,368.01% 1,844.34% 1,323.08% 648.81% 331.71% -162.92% 610.58%
Net Working Capital to Revenue		 8,964.15% 6,024.13% 8,911.12% 5,562.28% 2,368.01% 1,844.34% 1,323.08% 648.81% 331.71% -162.92% 610.58%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.64) ($0.11) ($0.33) ($0.50) ($0.13) ($0.20) ($0.64) ($0.30) ($0.33) ($0.31) ($0.12)
Adjusted Weighted Average Basic Shares Outstanding		 4.57M 4.22M 6.67M 8.12M 8.12M 7.76M 8.36M 8.74M 9.12M 8.99M 17.73M
Adjusted Diluted Earnings per Share		 ($0.64) $0.54 ($0.33) ($0.50) ($0.13) ($0.20) ($0.64) ($0.30) ($0.33) ($0.31) ($0.12)
Adjusted Weighted Average Diluted Shares Outstanding		 4.57M 4.22M 6.67M 8.12M 8.12M 7.76M 8.36M 8.74M 9.12M 8.99M 17.73M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.71M 6.77M 6.77M 6.92M 6.92M 7.50M 7.50M 7.98M 8.88M 25.48M 25.48M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.17 -2.25 -2.88 -1.73 -1.60 -1.88 -3.37 -2.31 -2.60 -2.68 -2.37
Normalized NOPAT Margin		 -7,078.53% -11,681.23% -8,218.50% -1,939.58% -685.31% -4,348.96% -13,461.10% -762.84% -22,002.61% -13,661.79% -10,228.80%
Pre Tax Income Margin		 15,531.79% -11,937.79% -6,352.16% -4,521.39% -467.22% -3,778.63% -21,359.20% -875.79% -25,748.11% -16,365.49% -9,298.25%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.28% 0.00% 0.00% -1.25% -6.36%

Financials Breakdown Chart

Key Financial Trends

BioRestorative Therapies’ recent financial statements show a development-stage company with modest and highly inconsistent revenue, substantial research and development spending, recurring operating losses and continued reliance on external financing.

  • Quarterly net loss improved year over year. Q1 2026 net loss was $2.15 million, compared with a restated loss of $5.34 million in Q1 2025 and a loss of $1.64 million in Q4 2024. The improvement reflects lower operating expenses, particularly research and development costs.
  • Operating expenses declined from the prior year. Q1 2026 operating expenses were $3.40 million, down from $4.83 million in Q1 2025. Research and development expense fell to $1.93 million from $2.65 million, while selling, general and administrative expense declined to $1.48 million from $2.18 million.
  • The balance sheet remains free of noncurrent debt. BioRestorative reported no noncurrent liabilities as of March 31, 2026. Current assets of $3.80 million exceeded current liabilities of $1.61 million, producing a current ratio of approximately 2.4.
  • Equity financing provided a near-term cash inflow. The company issued $5.0 million of common equity in Q1 2026, resulting in $4.44 million of net financing cash flow after a $559,000 share repurchase. This helped offset operating cash burn and produced a quarterly increase in cash of $1.60 million.
  • Revenue remains too small and volatile to establish a clear growth trend. Revenue was $23,000 in Q1 2026, compared with $25,000 in Q1 2025, $303,000 in Q2 2025, $12,000 in Q3 2025 and $20,000 in Q4 2025. Although gross margins were generally positive, gross profit was only $16,000 in Q1 2026 and did not cover operating expenses.
  • Other income has reduced reported losses but is not a substitute for operating revenue. Q1 2026 included $1.23 million of net other income, compared with $618,000 in Q4 2025. Similar investment and other-income benefits appeared in earlier periods, meaning reported results may be influenced by non-operating items rather than commercial growth.
  • Operations continue to consume substantial cash. Net cash used in operating activities increased to $3.81 million in Q1 2026 from $2.42 million in Q4 2025 and $2.90 million in Q3 2025. The company has reported negative operating cash flow in each provided quarter since at least Q3 2023.
  • Liquidity has deteriorated materially over the longer period. Cash and short-term investments totaled $3.59 million at March 31, 2026, down from $6.26 million at September 30, 2025, $9.11 million at March 31, 2025 and $13.05 million at September 30, 2024. The Q1 2026 cash and investment balance was slightly below the quarter’s operating cash burn, highlighting potential financing needs if spending continues at a similar pace.
  • Accumulated losses remain significant. Retained earnings were negative $172.1 million at March 31, 2026. Total equity was only $3.03 million against $175.1 million of common stock, indicating that historical losses have substantially reduced the company’s net asset base.
  • Shareholder dilution is a continuing risk. The weighted-average basic share count rose to 17.7 million in Q1 2026 from 8.4 million in Q1 2025 and 6.7 million in Q1 2024. The company’s dependence on common-equity issuance to fund operations could further dilute existing shareholders.

Overall, the latest quarter showed better earnings than the year-ago period and a stronger current-liability position, but the improvement remains fragile. Investors should focus on whether BioRestorative can generate recurring operating revenue, reduce cash burn and fund research programs without continued substantial equity issuance.

09/09/26 11:44 PM ETAI Generated. May Contain Errors.

BioRestorative Therapies Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BioRestorative Therapies' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

BioRestorative Therapies' net income appears to be on an upward trend, with a most recent value of -$14.24 million in 2025, falling from $0.00 in 2015. The previous period was -$8.98 million in 2024.

BioRestorative Therapies' total operating income in 2025 was -$15.65 million, based on the following breakdown:
  • Total Gross Profit: $335.86 thousand
  • Total Operating Expenses: $15.98 million

Over the last 10 years, BioRestorative Therapies' total revenue changed from $0.00 in 2015 to $359.70 thousand in 2025, a change of 35,970,000.0%.

BioRestorative Therapies' total liabilities were at $3.72 million at the end of 2025, a 0.7% decrease from 2024, and a 372,289,100.0% increase since 2015.

In the past 10 years, BioRestorative Therapies' cash and equivalents has ranged from $0.00 in 2015 to $21.03 million in 2021, and is currently $1.51 million as of their latest financial filing in 2025.

Over the last 10 years, BioRestorative Therapies' book value per share changed from 0.00 in 2015 to 0.04 in 2025, a change of 3.9%.


Related Companies

Financial statements for OTCMKTS:BRTXQ last updated on 9/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel